New pill targets tough cancers: early trial launches
NCT ID NCT06704724
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 31 times
Summary
This early-stage study tests a new oral medication, PF-07985045, alone or with other cancer drugs, in people with advanced solid tumors that have a KRAS gene mutation. The cancers studied include non-small cell lung, colorectal, and pancreatic cancers. The main goals are to check safety and find the best dose. About 30 participants will take the pill in 21- or 28-day cycles and be followed for up to 4 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
City of Hope (City of Hope National Medical Center, City Of Hope Medical Center)
Duarte, California, 91010, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
DFCI Chestnut Hill
Newton, Massachusetts, 02467, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Highlands Oncology Group
Fayetteville, Arkansas, 72703, United States
-
Highlands Oncology Group
Rogers, Arkansas, 72758, United States
-
Highlands Oncology Group
Springdale, Arkansas, 72762, United States
-
Pan American Center for Oncology Trials, LLC
Rio Piedras, 00935, Puerto Rico
-
The Trustees of Columbia University and The New York and Presbyterian Hospital
New York, New York, 10032, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Madison, Wisconsin, 53718, United States
-
University of Wisconsin Carbone Cancer Center-University Hospital
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.